US 12,391,646 B2
Using adiponectin receptor agonists to treat inflammation and bone diseases in diabetes
Jinkun Chen, Lexington, MA (US); Qisheng Tu, Newton, MA (US); Xingwen Wu, Boston, MA (US); Gang Chen, Shanghai (CN); and Wei Qiu, Boston, MA (US)
Assigned to Trustees of Tufts College, Medford, MA (US)
Filed by Trustees of Tufts College, Medford, MA (US)
Filed on May 21, 2024, as Appl. No. 18/670,680.
Application 18/670,680 is a continuation of application No. 18/299,266, filed on Apr. 12, 2023, granted, now 12,098,131.
Application 18/299,266 is a continuation of application No. 17/550,834, filed on Dec. 14, 2021, granted, now 11,655,212, issued on May 23, 2023.
Claims priority of provisional application 63/125,362, filed on Dec. 14, 2020.
Prior Publication US 2024/0376053 A1, Nov. 14, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 211/58 (2006.01); A61P 19/08 (2006.01); A61P 29/00 (2006.01)
CPC C07D 211/58 (2013.01) [A61P 19/08 (2018.01); A61P 29/00 (2018.01)] 20 Claims
 
1. A compound of formula

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein R1 is —C(═O)R4 and R4 is a chloro-substituted phenyl; R2 is a C1-C4 alkoxyl, hydrogen, or 3,4-dichloro; R3 is hydrogen or a C1-C4 alkyl; and R2 and R3 are not both hydrogen; or
wherein R1 is —C(═O)R4 and R4 is an unsubstituted phenyl; R2 is a C1-C4 alkoxyl or hydrogen, or 3,4-dichloro; R3 is hydrogen or a C1-C4 alkyl; and R2 and R3 are not both hydrogen; or
wherein R1 is —C(═O)R4 and R4 is methyl; R2 is a C1-C4 alkoxyl or hydrogen; R3 is hydrogen or a C1-C4 alkyl; and R2 and R3 are not both hydrogen; or
wherein R1 is an unsubstituted phenyl; and R2 is a C1-C4 alkoxyl and R3 is hydrogen or a C1-C4 alkyl or R2 is hydrogen and R3 is hydrogen.